Short answer
Idexx Laboratories (IDXX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1.2B (up 9.7% year over year) with net income of $338M.
Q2 2026 key financials · XBRL
- Revenue
- $1.2B
- +9.7% YoY · +6.6% QoQ
- Net income
- $338M
- +15.1% YoY · +21.5% QoQ
- Operating margin
- 35.0%
- Gross margin
- 64.0%
- EPS (diluted)
- $4.27
- +17.6% YoY · +23.1% QoQ
Source: XBRL data from the Idexx Laboratories (IDXX) Q2 2026 10-Q on SEC EDGAR. USD.
Idexx Laboratories Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, or earnings figures provided in the supplied text
- Near-term risks: geopolitical instability, tariffs, inflation, severe weather, supply-chain challenges, and economic uncertainty
Risk Factors
- Share repurchases: 581,800 shares bought under the program during Q2 2026
- Repurchase authorization: 2,552,570 shares remaining under the 78 million-share program
- Capital allocation exposure: $576.70 average April repurchase price
- Tax compliance: 1% excise tax on open-market repurchases, net of eligible stock issuances
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Idexx Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.